

AG Kolon-/Rektum-/Dünndarntumore

Kontakt Daten

Sprecher der Arbeitsgruppe

Prof. Dr. Sebastian Stintzing
Charité – Universitätsmedizin Berlin
Medizinische Klinik mit Schwerpunkt
Hämatologie, Onkologie und Tumorimmunologie
Charitéplatz 1, 10117 Berlin
Tel: +49 (0)30 450 513 002
stintzing@aio-portal.de

Prof. Dr. Ralf-Dieter Hofheinz
Universitätsmedizin Mannheim
Interdisziplinäres Tumorzentrum
Theodor-Kutzer-Ufer 1 - 3, 68167 Mannheim
Tel: +49 (0)621 3832855
hofheinz@aio-portal.de

Leitgruppe

Prof. Dr. Dirk Arnold, Hamburg
Prof. Dr. Gunnar Folprecht, Dresden
Prof. Dr. Michael Geißler, Esslingen
Prof. Dr. Susanna Hegewisch-Becker, Hamburg
Prof. Dr. Volker Heinemann, München
Prof. Dr. Stefan Kasper, Essen
Prof. Dr. Stefan Kubicka, Reutlingen
PD Dr. Dominik P. Modest, Berlin
Prof. Dr. Anke Reinacher-Schick, Bochum
Prof. Dr. Thomas Seufferlein, Ulm
PD Dr. Alexander Stein, Hamburg

AG Kolon-/Rektum-/Dünndarntumore

Frühjahrstreffen 2020: Aktuell rekrutierende Studien 1

- 1. AIO-KRK-0212 (PANAMA):** Randomized phase II study for evaluation of efficacy and safety of maintenance treatment with 5-FU/FA plus panitumumab vs. 5-FU/FA alone after prior induction treatment with mFOLFOX6 plus panitumumab and re-induction with mFOLFOX6 plus panitumumab in case of progression for first-line treatment of patients with metastatic colorectal cancer (PanaMa); LKP: **D.P. Modest**
- 2. AIO-KRK-0413/ass (COLOPREDICT PLUS):** Retro- und prospektive Erfassung der Rolle von MSI und KRAS für die Prognose beim Kolonkarzinom im Stadium II + III; LKP: **A. Reinacher-Schick**
- 3. AIO-KRK-0114 (FIRE-4):** Randomisierte Studie zur Wirksamkeit einer Cetuximab-Reexposition bei Patienten mit metastasiertem kolorektalem Karzinom (RAS Wildtyp) welche auf eine Erstlinien-Behandlung mit FOLFIRI plus Cetuximab ein Ansprechen zeigten (FIRE-4); LKP: **V. Heinemann**
- 4. AIO-KRK-0214:** mFOLFOX6 vs. mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial; LKP: **R. Hofheinz**
- 5. AIO-KRK-0116 (FIRE-4.5):** Randomised phase-II study to investigate FOLFOXIRI plus Cetuximab vs. FOLFOXIRI plus Bevacizumab as first-line treatment of BRAF-mutant metastatic colorectal cancer; LKP: **V. Heinemann**

AG Kolon-/Rektum-/Dünndarntumore

Frühjahrstreffen 2020: Aktuell rekrutierende Studien 2

6. **AIO-KRK-0316/ass (RAMTAS)**: A Phase IIb study with run in safety phase of Ramucirumab in combination with TAS102 vs. TAS102 monotherapy in chemotherapy refractory metastatic colorectal cancer patients; LKP: **S. Kasper-Virchow**
7. **AIO-KRK-0117 (Elderly)**: Aflibercept and 5-FU vs. FOLFOX as 1st line treatment option for elderly or frail elderly patients with metastatic colorectal cancer; LKP: **R. Hofheinz**
8. **AIO-KRK-0217 (CIRCULATE)**: Circulating tumor DNA based decision for adjuvant treatment in colon cancer stage II evaluation; LKP: **G. Folprecht**
9. **AIO-KRK-0118 (FIRE-6)**: Avelumab added to FOLFIRI plus Cetuximab followed by Avelumab maintenance in patients with previously untreated RAS wild-type colorectal cancer; LKP: **V. Heinemann**
10. **AIO-KRK-0119 (MEFOX)**: A phase I/II trial of methadone hydrochloride and mFOLFOX6 in the treatment of advanced colorectal cancer; LKP: **T. Seufferlein**
11. **AIO-KRK-0419 (ACO/ARO/AIO-18.1)**: AIO-KRK-0419: Preoperative oxaliplatin-based chemoradiotherapy and consolidation chemotherapy versus fluorouracil-based chemoradiotherapy for MRI-defined intermediate and high-risk rectal cancer patients - ACO/ARO/AIO-18.1; LKP **C. Rödel**

AG Kolon-/Rektum-/Dünndarmtumore

Frühjahrstreffen 2020: Geplante Studien

1. **AIO-KRK-0418 (PORT)**: Post-resection therapy in patients with colorectal cancer; LKP: **D.P. Modest**
2. **AIO-KRK-0120 (FIRE-7)**: Benefit of central tumor board review for secondary resectability of untreated RAS mutant metastatic colorectal cancer (mCRC) patients treated with FOLFOXIRI plus Bevacizumab); LKP: **V. Heinemann**
3. **AIO-KRK/YMO-0519 (FIRE-8)**: First-line combinations of Trifluridin/Tipiracil with biologicals; LKP: **D.P. Modest**
4. **AIO-KRK-0115/xx (CELIM3)**: Comparative Evaluation of the quality of Life adjusted survival between surgical and non-surgical treatment of Metastatic colorectal cancer patients; LKP: **G. Folprecht**
5. **AIO-KRK-0317 (ATOMIC)**: Randomized trial of FOLFOX alone or combined with Atezolizumab as adjuvant therapy of patients with stage III colon cancer with deficient DNA mismatch repair or microsatellite instability; LKP: **A. Reinacher-Schick**
6. **AIO-KRK-0319 (ACO/ARO/AIO-18.2)**: Preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure: A randomized phase III trial of the German Rectal Cancer Study Group; LKP: **R. Hofheinz**